Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemia
Authors' conclusion
This analysis suggests that FGF-5 could be a biomarker to discriminate individuals living with FH from HC individuals.
Study context
- Population
- Individuals with familial hypercholesterolaemia, hypercholesterolaemic individuals and controls
- Comparison
- Plasma protein biomarkers in familial hypercholesterolaemia (FH) vs hypercholesterolaemic (HC) and control individuals
- Outcome
- Plasma biomarkers (panel of 264 proteins) distinguishing FH from HC and control individuals
Methodological detailsmachine learning, low-density lipoprotein cholesterol (LDL-C)-matched comparison
- Machine learning
- LDL-C-matched comparison
Performance
As reported in the abstract
Plasma FGF-5 discriminating FH
Mean AUC
> .990
P < 0.001
genFH and clinFH vs Controls · elevated FGF-5
Mean AUC
>.990
P < 0.001
genFH and clinFH vs HC · elevated FGF-5, even after matching for LDL-C
Further findings
FGF-5 by immunoenzymatic assay
- FGF-5 elevated in genFH and clinFH in all cohorts analysed
Original publication
Fibroblast growth factor 5: a novel biomarker for familial hypercholesterolaemia. Eur Heart J. Published 10 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →